- GlobeNewswire•3 months agoNymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy
HASBROUCK HEIGHTS, N.J., Nov. 29, 2016-- Nymox Pharmaceutical Corporation is pleased to announce that new Phase 3 prospective randomized clinical trial results have confirmed that patients who received ...
- 24/7 Wall St.•5 months ago
Nymox Pharmaceutical shares jumped following the announcement of positive results from its late-stage prostate cancer trial.
NYMX : Summary for Nymox Pharmaceutical Corporatio - Yahoo Finance
Nymox Pharmaceutical Corporation (NYMX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||3.26 x 100|
|Ask||3.92 x 100|
|Day's Range||3.45 - 3.60|
|52 Week Range||1.62 - 5.79|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-10.42|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|